Company intelligence
BrainChild Bio
BrainChild Bio is harnessing the power of CAR-T cell technology for tumors in the central nervous system.
About BrainChild Bio
We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.
Verified activity
Signals from BrainChild Bio
6 published signals
Capital & Finance
BrainChild Bio secured $116 million Series A financing.
Reported by BrainChild Bio
Research & Knowledge
BrainChild Bio is currently conducting the pivotal ILLUMINATE trial for children with DIPG.
Reported by BrainChild Bio
Research & Knowledge
BrainChild Bio announced the initiation of ILLUMINATE, a Phase 2 registrational trial evaluating BCB-276, an investigational B7-H3-targeted autologous CAR T cell therapy for children and young adults with newly diagnosed DIPG.
Reported by BrainChild Bio
Capital & Finance
BrainChild Bio closed a $116 million Series A financing to support its pivotal Phase 2 clinical trial of BCB-276 for children with DIPG, advance additional CAR T cell therapies for pediatric and adult brain tumors, and continue building its next-generation CNS cell therapy platform.
Reported by BrainChild Bio
Presence & Recognition
Brainchild Bio dedicated the Sperring Family Garden just outside the Friends of Costco building that opened during Jeff Sperring's tenure as CEO.
Reported by Christopher Longhurst, MD
Products & Services
BrainChild Bio is focused on advancing cell therapies designed for pediatric brain tumors.
Reported by BrainChild Bio